# Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted

> **NCT02647489** · PHASE1 · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 66 (actual)

## Conditions studied

- Malaria, Antepartum

## Interventions

- **BIOLOGICAL:** PAMVAC
- **BIOLOGICAL:** Alhydrogel
- **BIOLOGICAL:** GLA-SE
- **BIOLOGICAL:** GLA-LSQ
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02647489
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2018-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02647489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02647489, "Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02647489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*